Baker Bros. Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Baker Bros. Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-142,000	Closed	-$760K	–	121
2016 Q4	$760K	Hold	142,000	–	–	0.01%	115
2016 Q3	$1.11M	Hold	142,000	–	–	0.01%	110
2016 Q2	$808K	Hold	142,000	–	–	0.01%	120
2016 Q1	$595K	Hold	142,000	–	–	0.01%	124
2015 Q4	$963K	Hold	142,000	–	–	0.01%	121
2015 Q3	$828K	Hold	142,000	–	–	0.01%	121
2015 Q2	$1.1M	Hold	142,000	–	–	0.01%	116
2015 Q1	$1.45M	Buy	+142,000	New	+$1.45M	0.01%	115

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baker Bros. Advisors's ALDX Position: Q1 2017 in Review

Baker Bros. Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2017, closing a stake of 142,000 shares — an estimated $760K sold.

Baker Bros. Advisors first reported a position in ALDX in Q1 2015 and held it in 8 quarters. The position peaked at $1.45M in Q1 2015. 24 funds tracked by Wall St. Rank hold ALDX as of Q1 2017.

Baker Bros. Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2017 after selling out during the quarter.
Baker Bros. Advisors sold 142,000 Aldeyra Therapeutics shares in Q1 2017, an estimated $760K.
Baker Bros. Advisors first reported a position in Aldeyra Therapeutics in Q1 2015 and held it in 8 quarters.
Baker Bros. Advisors's Aldeyra Therapeutics position peaked at $1.45M in Q1 2015.
24 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2017.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.